

Item_Num	Item_Name	NPCR	CoC	SEER	CDRI	Source_of_Standard	Note
10	Record Type	R	.	.	R	NAACCR	
20	Patient ID Number	R	.	R		Reporting Registry	
21	Patient System ID--Hosp	.	.	.		NAACCR	
30	Registry Type	.	.	.		NAACCR	
40	Registry ID	R	.	R	R	NAACCR	
45	NPI--Registry ID	.	.	R*	R	CMS	
50	NAACCR Record Version	R	.	R	R	NAACCR	
60	Tumor Record Number	R	.	R	R	NAACCR	
70	Addr at DX--City	R	R	R	R	CoC	
80	Addr at DX--State	R	R	R	R	CoC	
81	State at DX Geocode 1970/80/90	RH*	.	R		NAACCR	
82	State at DX Geocode 2000	D	.	D		NAACCR	
83	State at DX Geocode 2010	D	.	D		NAACCR	
84	State at DX Geocode 2020	D	.	D		NAACCR	
86	Geocoding Quality Code	D*	.	D		NAACCR	
87	Geocoding Quality Code Detail	D*	.	D		NAACCR	
89	County at DX Analysis	D	.	D		NAACCR	
90	County at DX Reported	R	R	R		FIPS/SEER	
94	County at DX Geocode 1970/80/90	RH*	.	D		NAACCR	
95	County at DX Geocode2000	D	.	D		NAACCR	
96	County at DX Geocode2010	D	.	D		NAACCR	
97	County at DX Geocode2020	D	.	D		NAACCR	
100	Addr at DX--Postal Code	R	R	R	R	CoC	
102	Addr at DX--Country	.	R	R	R	NAACCR	
110	Census Tract 1970/80/90	RH*	.	RH		SEER	
120	Census Cod Sys 1970/80/90	RH*	.	RH		SEER	
125	Census Tract 2020	D	.	D		NAACCR	
130	Census Tract 2000	RH	.	RH		NAACCR	
135	Census Tract 2010	R	.	R		NAACCR	
145	Census Tr Poverty Indictr	D	.	D		NAACCR	
150	Marital Status at DX	.	.	R	R	SEER	
160	Race 1	R	R	R	R	SEER/CoC	
161	Race 2	R	.	R	R	SEER	
162	Race 3	R	.	R	R	SEER	
163	Race 4	R	.	R	R	SEER	
164	Race 5	R	.	R	R	SEER	
190	Spanish/Hispanic Origin	R	R	R	R	SEER/CoC	
191	NHIA Derived Hisp Origin	D	.	D		NAACCR	
192	IHS Link	R*	.	R		NPCR	
193	Race--NAPIIA(derived API)	R	.	.		NAACCR	

194	IHS Purchased/Referred Care Delivery Area	D	.	D		NPCR	
200	Computed Ethnicity	.	.	D		SEER	
210	Computed Ethnicity Source	.	.	R		SEER	
225	Sex Assigned at Birth	R	R	R	R	NAACCR	New
230	Age at Diagnosis	R	R	R	R	SEER/CoC	
240	Date of Birth	R	R	R	R	SEER/CoC	
252	Birthplace--State	R*	R	R	R	NAACCR	
254	Birthplace--Country	R*	R	R	R	NAACCR	
272	Census Ind Code CDC	R*	.	.		Census/NPCR	
282	Census Occ Code CDC	R*	.	.		Census/NPCR	
284	Urban Indian Organization (UIO)	D	.	D		NPCR	
285	Urban Indian Organization (UIO) Service Area	D	.	D		NPCR	
290	Occupation Source	R*	.	.		NPCR	
300	Industry Source	R*	.	.		NPCR	
310	Text--Usual Occupation	R*	.	.	R	NPCR	
320	Text--Usual Industry	R*	.	.	R	NPCR	
331	Geocoding Accuracy Score	D*	.	D		NAACCR	New
332	Geocoding Accuracy Type	D*	.	D		NAACCR	New
339	RUCA 2000	D	.	D		NAACCR	
341	RUCA 2010	D	.	D		NAACCR	
342	RUCA 2020	D	.	D		NAACCR	New
344	Tobacco Use Smoking Status	R*	R	R*	R	NPCR	
345	URIC 2000	D	.	D		NAACCR	
346	URIC 2010	D	.	D		NAACCR	
347	URIC 2020	D	.	D		NAACCR	New
361	Census Block Group 2020	.	.	.		Census	
362	Census Block Group 2000	.	.	D		Census	
363	Census Block Group 2010	.	.	R		Census	
364	Census Tr Cert 1970/80/90	RH*	.	RH		SEER	
365	Census Tr Certainty 2000	RH	.	RH		NAACCR	
366	GIS Coordinate Quality	R*	.	D		NAACCR	
367	Census Tr Certainty 2010	R	.	R		NAACCR	
368	Census Block Grp 1970/80/90	.	.	D		Census	
369	Census Tract Certainty 2020	D	.	D		NAACCR	
380	Sequence Number--Central	R	.	R		SEER	
390	Date of Diagnosis	R	R	R	R	SEER/CoC	
400	Primary Site	R	R	R	R	SEER/CoC	
410	Laterality	R	R	R	R	SEER/CoC	
420	Histology (92-00) ICD-O-2	RH	RH	RH	RH	SEER/CoC	
430	Behavior (92-00) ICD-O-2	RH	RH	RH	RH	SEER/CoC	
440	Grade	RH	RH	RH	RH	SEER/CoC	

441	Grade Path Value	RH*	RH	RH	RH	AJCC	
442	Ambiguous Terminology DX	.	RH	RH	RH	SEER	
443	Date Conclusive DX	.	RH	RH	RH	SEER	
444	Mult Tum Rpt as One Prim	.	RH	RH	RH	SEER	
445	Date of Mult Tumors	.	RH	RH	RH	SEER	
446	Multiplicity Counter	.	RH	RH	RH	SEER	
449	Grade Path System	RH*	RH	RH	RH	AJCC	
450	Site Coding Sys--Current	R	.	.	R	NAACCR	
460	Site Coding Sys--Original	.	.	.		NAACCR	
470	Morph Coding Sys--Current	R	.	.	R	NAACCR	
480	Morph Coding Sys--Originl	.	.	.		NAACCR	
490	Diagnostic Confirmation	R	R	R	R	SEER/CoC	
500	Type of Reporting Source	R	.	R	R	SEER	
501	Casefinding Source	R*	.	.	R	NAACCR	
522	Histologic Type ICD-O-3	R	R	R	R	SEER/CoC	
523	Behavior Code ICD-O-3	R	R	R	R	SEER/CoC	
530	EDP MDE Link Date	RS	.	.		NPCR	
531	EDP MDE Link	RS	.	.		NPCR	
540	Reporting Facility	R	R	R	R	CoC	
545	NPI--Reporting Facility	R*	R	R*	R	CMS	
550	Accession Number--Hosp	.	R	R	R	CoC	
560	Sequence Number--Hospital	.	R	R	R	CoC	
570	Abstracted By	.	R	R	R	CoC	
580	Date of 1st Contact	R*	R	.	R	CoC	
590	Date of Inpt Adm	.	.	.		NAACCR	
600	Date of Inpt Disch	.	.	.		NAACCR	
610	Class of Case	R	R	R	R	CoC	
630	Primary Payer at DX	R*	R	R	R	CoC	
668	RX Hosp--Surg App 2010	.	R	.	R	CoC	
670	RX Hosp--Surg Prim Site 03-2022	.	R	RH	RH	CoC	
671	RX Hosp--Surg Prim Site 2023	.	R	R	R	CoC	
672	RX Hosp--Scope Reg LN Sur	.	R	R	R	CoC	
674	RX Hosp--Surg Oth Reg/Dis	.	R	R	R	CoC	
676	RX Hosp--Reg LN Removed	.	RH	.	RH	CoC	
682	Date Regional Lymph Node Dissection	.	R	RC	R	NAACCR	
690	RX Hosp--Radiation	.	.	RH	RH	SEER	
700	RX Hosp--Chemo	.	R	R	R	CoC	
710	RX Hosp--Hormone	.	R	R	R	CoC	
720	RX Hosp--BRM	.	R	R	R	CoC	
730	RX Hosp--Other	.	R	R	R	CoC	
740	RX Hosp--DX/Stg Proc	.	R	.	R	CoC	

746	RX Hosp--Surg Site 98-02	.	RH	RH	RH	CoC	
747	RX Hosp--Scope Reg 98-02	.	RH	RH	RH	CoC	
748	RX Hosp--Surg Oth 98-02	.	RH	RH	RH	CoC	
751	RX Hosp--Recon Breast	.	R	R	R	CoC	
752	Tumor Size Clinical	.	.	RH	RH	SEER	
754	Tumor Size Pathologic	.	.	RH	RH	SEER	
756	Tumor Size Summary	R	R	R	R	NPCR/CoC	
759	SEER Summary Stage 2000	RH	RH	RH	RH	SEER	
760	SEER Summary Stage 1977	RH	RH	.	RH	SEER	
762	Derived Summary Stage 2018	.	.	D		SEER	
764	Summary Stage 2018	R	.	R*	R	SEER	
772	EOD Primary Tumor	.	.	R	R	SEER	
774	EOD Regional Nodes	.	.	R	R	SEER	
776	EOD Mets	.	.	R	R	SEER	
780	EOD--Tumor Size	.	RH	RH	RH	SEER/CoC	
785	Derived EOD 2018 T	.	.	D		SEER	
790	EOD--Extension	.	.	RH	RH	SEER	
795	Derived EOD 2018 M	.	.	D		SEER	
800	EOD--Extension Prost Path	.	.	RH	RH	SEER	
810	EOD--Lymph Node Involv	.	.	RH	RH	SEER	
815	Derived EOD 2018 N	.	.	D		SEER	
818	Derived EOD 2018 Stage Group	.	.	D		SEER	
820	Regional Nodes Positive	R	R	R	R	SEER/CoC	
830	Regional Nodes Examined	R	R	R	R	SEER/CoC	
832	Date of Sentinel Lymph Node Biopsy	.	RS	R*	R	CoC	
834	Sentinel Lymph Nodes Examined	.	RS	RS	R	CoC	
835	Sentinel Lymph Nodes Positive	.	RS	RS	R	CoC	
840	EOD--Old 13 Digit	.	.	RH	RH	SEER	
850	EOD--Old 2 Digit	.	.	RH	RH	SEER	
860	EOD--Old 4 Digit	.	.	RH	RH	SEER	
870	Coding System for EOD	.	.	RH	RH	SEER	
880	TNM Path T	.	RH	RH	RH	AJCC	
890	TNM Path N	.	RH	RH	RH	AJCC	
900	TNM Path M	.	RH	RH	RH	AJCC	
910	TNM Path Stage Group	.	RH	RH*	RH	AJCC	
920	TNM Path Descriptor	.	RH	RH	RH	CoC	
930	TNM Path Staged By	.	RH	RH	RH	CoC	
940	TNM Clin T	.	RH	RH	RH	AJCC	
950	TNM Clin N	.	RH	RH	RH	AJCC	
960	TNM Clin M	.	RH	RH	RH	AJCC	
970	TNM Clin Stage Group	.	RH	RH*	RH	AJCC	

980	TNM Clin Descriptor	.	RH	RH	RH	CoC	
990	TNM Clin Staged By	.	RH	RH	RH	CoC	
995	AJCC ID	.	D	D		NAACCR	
1001	AJCC TNM Clin T	.	R	RC	R	AJCC	
1002	AJCC TNM Clin N	.	R	RC	R	AJCC	
1003	AJCC TNM Clin M	.	R	RC	R	AJCC	
1004	AJCC TNM Clin Stage Group	.	R	RC	R	AJCC	
1011	AJCC TNM Path T	.	R	RC	R	AJCC	
1012	AJCC TNM Path N	.	R	RC	R	AJCC	
1013	AJCC TNM Path M	.	R	RC	R	AJCC	
1014	AJCC TNM Path Stage Group	.	R	RC	R	AJCC	
1021	AJCC TNM Post Therapy Path (yp) T	.	R	RC	R	AJCC	
1022	AJCC TNM Post Therapy Path (yp) N	.	R	RC	R	AJCC	
1023	AJCC TNM Post Therapy Path (yp) M	.	R	RC	R	AJCC	
1024	AJCC TNM Post Therapy Path (yp) Stage Group	.	R	RC	R	AJCC	
1031	AJCC TNM Clin T Suffix	.	R	RC	R	AJCC	
1032	AJCC TNM Path T Suffix	.	R	RC	R	AJCC	
1033	AJCC TNM Post Therapy Path (yp) T Suffix	.	R	RC	R	AJCC	
1034	AJCC TNM Clin N Suffix	.	R	RC	R	AJCC	
1035	AJCC TNM Path N Suffix	.	R	RC	R	AJCC	
1036	AJCC TNM Post Therapy Path (yp) N Suffix	.	R	RC	R	AJCC	
1060	TNM Edition Number	.	R	RH	RH	CoC	
1062	AJCC TNM Post Therapy Clin (yc) T	.	R	RC	R	AJCC	
1063	AJCC TNM Post Therapy Clin (yc) T Suffix	.	R	RC	R	AJCC	
1064	AJCC TNM Post Therapy Clin (yc) N	.	R	RC	R	AJCC	
1065	AJCC TNM Post Therapy Clin (yc) N Suffix	.	R	RC	R	AJCC	
1066	AJCC TNM Post Therapy Clin (yc) M	.	R	RC	R	AJCC	
1067	AJCC TNM Post Therapy Clin (yc) Stage Group	.	.	.		AJCC	
1068	Grade Post Therapy Clin (yc)	R*	R	RS	R	NAACCR	
1112	Mets at DX-Bone	.	R	R	R	SEER	
1113	Mets at DX-Brain	.	R	R	R	SEER	
1114	Mets at Dx-Distant LN	.	R	R	R	SEER	
1115	Mets at DX-Liver	.	R	R	R	SEER	
1116	Mets at DX-Lung	.	R	R	R	SEER	
1117	Mets at DX-Other	.	R	R	R	SEER	
1132	Pediatric ID	.	.	RS*	R	NAACCR	
1133	Pediatric ID Version Current	.	.	RS*	R	NAACCR/SEER	
1134	Pediatric ID Version Original	.	.	RS*	R	NAACCR/SEER	
1135	Toronto Version Number	.	.	RS*	R	NAACCR/SEER	
1136	Pediatric Primary Tumor	.	.	RS*	R	NAACCR/SEER	
1137	Pediatric Regional Nodes	.	.	RS*	R	NAACCR/SEER	

1138	Pediatric Mets	.	.	RS*	R	NAACCR/SEER	
1142	Derived Pediatric T	.	.	RS*	R	NAACCR/SEER	
1143	Derived Pediatric N	.	.	RS*	R	NAACCR/SEER	
1144	Derived Pediatric M	.	.	RS*	R	NAACCR/SEER	
1145	Derived Pediatric Stage Group	.	.	RS*	R	NAACCR/SEER	
1146	Toronto T	.	.	R*	R	NAACCR/SEER	
1147	Toronto N	.	.	R*	R	NAACCR/SEER	
1148	Toronto M	.	.	R*	R	NAACCR/SEER	
1149	Toronto Stage Group	.	.	R*	R	NAACCR/SEER	
1150	Tumor Marker 1	.	RH	RH	RH	SEER	
1160	Tumor Marker 2	.	RH	RH	RH	SEER	
1170	Tumor Marker 3	.	RH	RH	RH	SEER	
1172	Post Transplant Lymphoproliferative Disorder-PTLD	RS*	R	RS	R	NAACCR	
1174	PD-L1	RS*	RS	RS	R	NAACCR	
1176	Spread Through Air Spaces (STAS)	.	RS	RC	R	NAACCR	NEW
1178	Residual Cancer Burden (RCB)	.	RS	RC	R	NAACCR	NEW
1179	Residual Cancer Burden Class	.	RS	RC	R	NAACCR	NEW
1182	Lymphovascular Invasion	R*	R	RS	R	AJCC	
1184	White Blood Cell Count	.	.	RS*	R	NAACCR/SEER	
1185	Intl Neuroblastoma Risk Grp Stag Sys (INRGSS)	.	.	RS*	R	NAACCR/SEER	
1186	n-MYC Amplification	.	.	RS*	R	NAACCR/SEER	
1187	Intl Neuroblastoma Path Prog Class (INPC)	.	.	RS*	R	NAACCR/SEER	
1188	IRSS Stage for Eye-2	.	.	RS*	R	NAACCR/SEER	
1189	Chromosome 16q: Loss of Heterozygosity	.	.	RS*	R	NAACCR/SEER	
1190	Chromosome 1q Status	.	.	RS*	R	NAACCR/SEER	
1191	EWSR1-FLI1 fusion	.	.	RS*	R	NAACCR/SEER	
1192	Pretext Clinical Staging	.	.	RS*	R	NAACCR/SEER	
1193	FOXO1 Gene Rearrangements	.	.	RS*	R	NAACCR/SEER	
1200	RX Date Surgery	R*	R	R	R	CoC	
1210	RX Date Radiation	R*	R	R	R	CoC	
1220	RX Date Chemo	R*	R	R	R	CoC	
1230	RX Date Hormone	R*	R	R	R	CoC	
1240	RX Date BRM	R*	R	R	R	CoC	
1250	RX Date Other	R*	R	R	R	CoC	
1260	Date Initial RX SEER	R#*	.	R	R	SEER	
1270	Date 1st Crs RX CoC	R#*	R	.	R	CoC	
1280	RX Date DX/Stg Proc	.	R	.	R	CoC	
1285	RX Summ--Treatment Status	R#	R	R	R	SEER/CoC	
1290	RX Summ--Surg Prim Site 03-2022	RH	R	RH	RH	SEER/CoC	
1291	RX Summ--Surg Prim Site 2023	R	R	R	R	SEER/CoC	
1292	RX Summ--Scope Reg LN Sur	R	R	R	R	SEER/CoC	

1294	RX Summ--Surg Oth Reg/Dis	R	R	R	R	SEER/CoC	
1296	RX Summ--Reg LN Examined	.	RH	RH	RH	SEER/CoC	
1310	RX Summ--Surgical Approch	.	RH	.	RH	CoC	
1320	RX Summ--Surgical Margins	.	R	R*	R	CoC	
1330	RX Summ--Reconstruct 1st	.	RH	.	RH	SEER	
1335	RX Summ--Recon Breast	.	R	R	R	CoC	
1340	Reason for No Surgery	R	R	R	R	SEER/CoC	
1350	RX Summ--DX/Stg Proc	.	R	.	R	CoC	
1360	RX Summ--Radiation	RH	.	RH	RH	SEER	
1370	RX Summ--Rad to CNS	.	.	RH	RH	SEER/CoC	
1380	RX Summ--Surg/Rad Seq	R	R	R	R	SEER/CoC	
1390	RX Summ--Chemo	R	R	R	R	SEER/CoC	
1400	RX Summ--Hormone	R	R	R	R	SEER/CoC	
1410	RX Summ--BRM	R	R	R	R	SEER/CoC	
1420	RX Summ--Other	R	R	R	R	SEER/CoC	
1430	Reason for No Radiation	R	R	R	R	CoC	
1460	RX Coding System--Current	R	.	.	R	NAACCR	
1501	Phase I Dose per Fraction	.	R	R*	R	CoC	
1502	Phase I Radiation External Beam Planning Tech	.	R	RC	R	CoC	
1503	Phase I Number of Fractions	.	R	R*	R	CoC	
1504	Phase I Radiation Primary Treatment Volume	.	R	R*	R	CoC	
1505	Phase I Radiation to Draining Lymph Nodes	.	R	R*	R	CoC	
1506	Phase I Radiation Treatment Modality	R	R	R	R	CoC	
1507	Phase I Total Dose	.	R	R*	R	CoC	
1511	Phase II Dose per Fraction	.	R	R*	R	CoC	
1512	Phase II Radiation External Beam Planning Tech	.	R	RC	R	CoC	
1513	Phase II Number of Fractions	.	R	R*	R	CoC	
1514	Phase II Radiation Primary Treatment Volume	.	R	R*	R	CoC	
1515	Phase II Radiation to Draining Lymph Nodes	.	R	R*	R	CoC	
1516	Phase II Radiation Treatment Modality	.	R	R	R	CoC	
1517	Phase II Total Dose	.	R	R*	R	CoC	
1521	Phase III Dose per Fraction	.	R	R*	R	CoC	
1522	Phase III Radiation External Beam Planning Tech	.	R	RC	R	CoC	
1523	Phase III Number of Fractions	.	R	R*	R	CoC	
1524	Phase III Radiation Primary Treatment Volume	.	R	R*	R	CoC	
1525	Phase III Radiation to Draining Lymph Nodes	.	R	R*	R	CoC	
1526	Phase III Radiation Treatment Modality	.	R	R	R	CoC	
1527	Phase III Total Dose	.	R	R*	R	CoC	
1531	Radiation Treatment Discontinued Early	.	R	R*	R	CoC	
1532	Number of Phases of Rad Treatment to this Volume	.	R	R*	R	CoC	
1533	Total Dose	.	R	R*	R	CoC	

1550	Rad--Location of RX	.	R	.	R	CoC	
1570	Rad--Regional RX Modality	RH	.	.	RH	CoC	
1632	Neoadjuvant Therapy	.	.	R	R	SEER	
1633	Neoadjuvant Therapy-Clinical Response	.	.	R	R	SEER	
1634	Neoadjuvant Therapy-Treatment Effect	.	.	R	R	SEER	
1639	RX Summ--Systemic/Sur Seq	R	R	R	R	CoC	
1640	RX Summ--Surgery Type	.	.	RH	RH	SEER	
1646	RX Summ--Surg Site 98-02	.	RH	.	RH	SEER/CoC	
1647	RX Summ--Scope Reg 98-02	.	RH	RH	RH	SEER/CoC	
1648	RX Summ--Surg Oth 98-02	.	RH	RH	RH	SEER/CoC	
1660	Subsq RX 2nd Course Date	.	.	.		CoC	
1671	Subsq RX 2nd Course Surg	.	.	.		CoC	
1672	Subsq RX 2nd Course Rad	.	.	.		CoC	
1673	Subsq RX 2nd Course Chemo	.	.	.		CoC	
1674	Subsq RX 2nd Course Horm	.	.	.		CoC	
1675	Subsq RX 2nd Course BRM	.	.	.		CoC	
1676	Subsq RX 2nd Course Oth	.	.	.		CoC	
1677	Subsq RX 2nd--Scope LN SU	.	.	.		CoC	
1678	Subsq RX 2nd--Surg Oth	.	.	.		CoC	
1679	Subsq RX 2nd--Reg LN Rem	.	.	.		CoC	
1680	Subsq RX 3rd Course Date	.	.	.		CoC	
1691	Subsq RX 3rd Course Surg	.	.	.		CoC	
1692	Subsq RX 3rd Course Rad	.	.	.		CoC	
1693	Subsq RX 3rd Course Chemo	.	.	.		CoC	
1694	Subsq RX 3rd Course Horm	.	.	.		CoC	
1695	Subsq RX 3rd Course BRM	.	.	.		CoC	
1696	Subsq RX 3rd Course Oth	.	.	.		CoC	
1697	Subsq RX 3rd--Scope LN Su	.	.	.		CoC	
1698	Subsq RX 3rd--Surg Oth	.	.	.		CoC	
1699	Subsq RX 3rd--Reg LN Rem	.	.	.		CoC	
1700	Subsq RX 4th Course Date	.	.	.		CoC	
1711	Subsq RX 4th Course Surg	.	.	.		CoC	
1712	Subsq RX 4th Course Rad	.	.	.		CoC	
1713	Subsq RX 4th Course Chemo	.	.	.		CoC	
1714	Subsq RX 4th Course Horm	.	.	.		CoC	
1715	Subsq RX 4th Course BRM	.	.	.		CoC	
1716	Subsq RX 4th Course Oth	.	.	.		CoC	
1717	Subsq RX 4th--Scope LN Su	.	.	.		CoC	
1718	Subsq RX 4th--Surg Oth	.	.	.		CoC	
1719	Subsq RX 4th--Reg LN Rem	.	.	.		CoC	
1750	Date of Last Contact	R	R	R	R	SEER/CoC	

1755	Date of Death--Canada	.	.	.		CCCR	
1760	Vital Status	R	R	R	R	SEER/CoC	
1762	Vital Status Recode	D	.	D		NAACCR	
1770	Cancer Status	.	R	R*	R	CoC	
1772	Date of Last Cancer (tumor) Status	.	R	R*	R	CoC	
1775	Record Number Recode	D	.	D		NAACCR	
1782	Surv-Date Active Followup	D	.	D		NAACCR	
1783	Surv-Flag Active Followup	D	.	D		NAACCR	
1784	Surv-Mos Active Followup	D	.	D		NAACCR	
1785	Surv-Date Presumed Alive	D	.	D		NAACCR	
1786	Surv-Flag Presumed Alive	D	.	D		NAACCR	
1787	Surv-Mos Presumed Alive	D	.	D		NAACCR	
1788	Surv-Date DX Recode	D	.	D		NAACCR	
1790	Follow-Up Source	R*	R	R*	R	CoC	
1791	Follow-up Source Central	R	.	R		NAACCR	
1800	Next Follow-Up Source	.	R	.	R	CoC	
1810	Addr Current--City	.	.	R	R	SEER	
1820	Addr Current--State	.	.	R	R	SEER	
1830	Addr Current--Postal Code	.	.	R	R	SEER	
1832	Addr Current--Country	.	.	R	R	NAACCR	
1840	County--Current	.	.	.		NAACCR	
1842	Follow-Up Contact--City	.	.	.		SEER	
1844	Follow-Up Contact--State	.	.	.		SEER	
1846	Follow-Up Contact--Postal	.	.	.		SEER	
1847	FollowUp Contact--Country	.	.	.		NAACCR	
1850	Unusual Follow-Up Method	.	.	.		NAACCR	
1854	No Patient Contact Flag	.	.	R	R	NAACCR	
1856	Reporting Facility Restriction Flag	.	.	R		NAACCR	
1860	Recurrence Date--1st	.	R	R*	R	CoC	
1880	Recurrence Type--1st	.	R	R*	R	CoC	
1910	Cause of Death	R	.	R		SEER	
1914	SEER Cause Specific COD	D	.	D		SEER	
1915	SEER Other COD	D	.	D		SEER	
1920	ICD Revision Number	R	.	R	R	SEER	
1930	Autopsy	.	.	.		NAACCR	
1942	Place of Death--State	R	.	R		NAACCR	
1944	Place of Death--Country	R*	.	R		NAACCR	
1960	Site (73-91) ICD-O-1	.	.	RH	RH	SEER	
1971	Histology (73-91) ICD-O-1	.	.	RH	RH	SEER	
1972	Behavior (73-91) ICD-O-1	.	.	RH	RH	SEER	
1973	Grade (73-91) ICD-O-1	.	.	RH	RH	SEER	

1975	Derived Summary Grade 2018	D		D		SEER	
1981	Over-ride SS/NodesPos	.	.	RH	RH	NAACCR	
1982	Over-ride SS/TNM-N	.	.	RH	RH	NAACCR	
1983	Over-ride SS/TNM-M	.	.	RH	RH	NAACCR	
1985	Over-ride Acsn/Class/Seq	.	.	.		NAACCR	
1986	Over-ride HospSeq/DxConf	.	.	.		NAACCR	
1987	Over-ride CoC-Site/Type	.	.	.		NAACCR	
1988	Over-ride HospSeq/Site	.	.	.		NAACCR	
1989	Over-ride Site/TNM-StgGrp	.	.	R	R	NAACCR	
1990	Over-ride Age/Site/Morph	R	.	R	R	SEER	
1992	Over-ride TNM Stage	.	.	.		NAACCR	
1993	Over-ride TNM Tis	.	.	R	R	NAACCR	
1994	Over-ride TNM 3	.	.	.		NAACCR	
2000	Over-ride SeqNo/DxConf	R	.	R	R	SEER	
2010	Over-ride Site/Lat/SeqNo	R	.	R	R	SEER	
2020	Over-ride Surg/DxConf	R	.	R	R	SEER	
2030	Over-ride Site/Type	R	.	R	R	SEER	
2040	Over-ride Histology	R	.	R	R	SEER	
2050	Over-ride Report Source	R	.	R	R	SEER	
2060	Over-ride Ill-define Site	R	.	R	R	SEER	
2070	Over-ride Leuk, Lymphoma	R	.	R	R	SEER	
2071	Over-ride Site/Behavior	R	.	R	R	SEER	
2072	Over-ride Site/EOD/DX Dt	.	.	R	R	SEER	
2073	Over-ride Site/Lat/EOD	.	.	R	R	SEER	
2074	Over-ride Site/Lat/Morph	R	.	R	R	SEER	
2078	Over-ride Name/Sex Assigned at Birth	R	.	R	R	NAACCR	
2085	Date Case Initiated	.	.	.		NAACCR	
2090	Date Case Completed	.	.	.		NAACCR	
2092	Date Case Completed--CoC	.	D	.		CoC	
2100	Date Case Last Changed	.	D	.		NAACCR	
2110	Date Case Report Exported	R	.	R	R	NPCR	
2111	Date Case Report Received	R	.	R	R	NPCR	
2112	Date Case Report Loaded	R	.	R	R	NPCR	
2113	Date Tumor Record Availbl	R	.	D	R	NPCR	
2116	ICD-O-3 Conversion Flag	R	.	R	R	SEER	
2117	Schema ID Version Current	D	D	D		SEER	
2118	Schema ID Version Original	D	D	D		SEER	
2140	CoC Coding Sys--Current	.	.	.		CoC	
2150	CoC Coding Sys--Original	.	.	.		CoC	
2152	CoC Accredited Flag	R	.	R	R	NPCR	
2156	AJCC API Version Current	.	D	D*		AJCC	

2157	AJCC API Version Original	.	D	D*		AJCC	
2158	AJCC Cancer Surveillance DLL Version Current	D	D	.		AJCC	
2159	AJCC Cancer Surveillance DLL Version Original	D	D	.		AJCC	
2170	Vendor Name	.	R	.	R	NAACCR	
2230	Name--Last	R	S	R	R	SEER	
2232	Name--Birth Surname	R	S	R	R	NAACCR	
2240	Name--First	R	S	R	R	SEER	
2250	Name--Middle	R	S	R	R	SEER	
2260	Name--Prefix	.	.	.		NAACCR	
2270	Name--Suffix	.	.	R	R	NAACCR	
2280	Name--Alias	R	S	R	R	NAACCR	
2290	Name--Spouse/Parent	.	.	.		NAACCR	
2300	Medical Record Number	R	.	R	R	NAACCR	
2315	Medicare Beneficiary Identifier	R*	.	.	R	NAACCR	
2320	Social Security Number	R	.	R	R	SEER	
2330	Addr at DX--No & Street	R	.	R	R	SEER	
2335	Addr at DX--Supplementl	R	.	R	R	SEER	
2350	Addr Current--No & Street	.	.	R	R	SEER	
2352	Latitude	R*	.	D		NAACCR	
2354	Longitude	R*	.	D		NAACCR	
2355	Addr Current--Supplementl	.	.	R*	R	SEER	
2360	Telephone	.	.	R	R	SEER	
2380	DC State File Number	R	.	R*		State	
2392	Follow-Up Contact--No&St	.	.	.		SEER	
2393	Follow-Up Contact--Suppl	.	.	.		SEER	
2394	Follow-Up Contact--Name	.	.	.		SEER	
2410	Institution Referred From	.	.	.		CoC	
2415	NPI--Inst Referred From	.	R	.	R	CMS	
2420	Institution Referred To	.	.	.		CoC	
2425	NPI--Inst Referred To	.	R	.	R	CMS	
2440	Following Registry	.	.	RH	RH	CoC	
2445	NPI--Following Registry	.	.	RH*	RH	CMS	
2460	Physician--Managing	.	.	.		NAACCR	
2465	NPI--Physician--Managing	.	.	.		CMS	
2470	Physician--Follow-Up	.	.	R	R	CoC	
2475	NPI--Physician--Follow-Up	.	.	R*	R	CMS	
2480	Physician--Primary Surg	.	.	.		CoC	
2485	NPI--Physician--Primary Surg	.	R	.	R	CMS	
2490	Physician 3	.	.	.		CoC	
2495	NPI--Physician 3	.	R	.	R	CMS	
2500	Physician 4	.	.	.		CoC	

2505	NPI--Physician 4	.	R	.	R	CMS	
2508	EHR Reporting	.	.	.		NAACCR	
2520	Text--DX Proc--PE	R^	.	R	R	NPCR	
2530	Text--DX Proc--X-ray/Scan	R^	.	R	R	NPCR	
2540	Text--DX Proc--Scopes	R^	.	R	R	NPCR	
2550	Text--DX Proc--Lab Tests	R^	.	R	R	NPCR	
2560	Text--DX Proc--Op	R^	.	R	R	NPCR	
2570	Text--DX Proc--Path	R^	.	R	R	NPCR	
2580	Text--Primary Site Title	R^	.	R	R	NPCR	
2590	Text--Histology Title	R^	.	R	R	NPCR	
2600	Text--Staging	R^	.	R	R	NPCR	
2610	RX Text--Surgery	R^	.	R	R	NPCR	
2620	RX Text--Radiation (Beam)	R^	.	R	R	NPCR	
2630	RX Text--Radiation Other	R^	.	R	R	NPCR	
2640	RX Text--Chemo	R^	.	R	R	NPCR	
2650	RX Text--Hormone	R^	.	R	R	NPCR	
2660	RX Text--BRM	R^	.	R	R	NPCR	
2670	RX Text--Other	R^	.	R	R	NPCR	
2680	Text--Remarks	.	.	R	R	NPCR	
2690	Text--Place of Diagnosis	.	.	.		NPCR	
2800	CS Tumor Size	RH*	RH	RH*	RH	AJCC	
2810	CS Extension	RH*	RH	RH*	RH	AJCC	
2820	CS Tumor Size/Ext Eval	RH*	RH	RH*	RH	AJCC	
2830	CS Lymph Nodes	RH*	RH	RH*	RH	AJCC	
2840	CS Lymph Nodes Eval	RH*	RH	RH*	RH	AJCC	
2850	CS Mets at DX	RH*	RH	RH*	RH	AJCC	
2851	CS Mets at Dx-Bone	.	RH	RH	RH	AJCC	
2852	CS Mets at Dx-Brain	.	RH	RH	RH	AJCC	
2853	CS Mets at Dx-Liver	.	RH	RH	RH	AJCC	
2854	CS Mets at Dx-Lung	.	RH	RH	RH	AJCC	
2860	CS Mets Eval	RH*	RH	RH*	RH	AJCC	
2861	CS Site-Specific Factor 7	RH*	RH	RH	RH	AJCC	
2862	CS Site-Specific Factor 8	RH*	RH	RH	RH	AJCC	
2863	CS Site-Specific Factor 9	RH*	RH	RH	RH	AJCC	
2864	CS Site-Specific Factor10	RH*	RH	RH	RH	AJCC	
2865	CS Site-Specific Factor11	RH*	RH	RH	RH	AJCC	
2866	CS Site-Specific Factor12	RH*	RH	RH	RH	AJCC	
2867	CS Site-Specific Factor13	RH*	RH	RH	RH	AJCC	
2868	CS Site-Specific Factor14	RH*	RH	RH	RH	AJCC	
2869	CS Site-Specific Factor15	RH*	RH	RH	RH	AJCC	
2870	CS Site-Specific Factor16	RH*	RH	RH	RH	AJCC	

2871	CS Site-Specific Factor17	RH*	RH	RH	RH	AJCC	
2872	CS Site-Specific Factor18	.	RH	RH	RH	AJCC	
2873	CS Site-Specific Factor19	.	RH	RH	RH	AJCC	
2874	CS Site-Specific Factor20	.	RH	RH	RH	AJCC	
2875	CS Site-Specific Factor21	.	RH	RH	RH	AJCC	
2876	CS Site-Specific Factor22	.	RH	RH	RH	AJCC	
2877	CS Site-Specific Factor23	.	RH	RH	RH	AJCC	
2878	CS Site-Specific Factor24	.	RH	RH	RH	AJCC	
2879	CS Site-Specific Factor25	RH*	RH	RH	RH	AJCC	
2880	CS Site-Specific Factor 1	RH*	RH	RH	RH	AJCC	
2890	CS Site-Specific Factor 2	RH*	RH	RH	RH	AJCC	
2900	CS Site-Specific Factor 3	RH*	RH	RH	RH	AJCC	
2910	CS Site-Specific Factor 4	RH*	RH	RH	RH	AJCC	
2920	CS Site-Specific Factor 5	RH*	RH	RH	RH	AJCC	
2930	CS Site-Specific Factor 6	RH*	RH	RH	RH	AJCC	
2935	CS Version Input Original	R*	RH	RH*	RH	AJCC	
2936	CS Version Derived	RH*	DH	D*	RH	AJCC	
2937	CS Version Input Current	R*	RH	RH*	RH	AJCC	
2940	Derived AJCC-6 T	.	DH	DH		AJCC	
2950	Derived AJCC-6 T Descript	.	DH	DH		AJCC	
2960	Derived AJCC-6 N	.	DH	DH		AJCC	
2970	Derived AJCC-6 N Descript	.	DH	DH		AJCC	
2980	Derived AJCC-6 M	.	DH	DH		AJCC	
2990	Derived AJCC-6 M Descript	.	DH	DH		AJCC	
3000	Derived AJCC-6 Stage Grp	.	DH	DH		AJCC	
3010	Derived SS1977	.	DH	DH		AJCC	
3020	Derived SS2000	RH*	DH	DH	RH	AJCC	
3030	Derived AJCC--Flag	.	DH	DH		AJCC	
3040	Derived SS1977--Flag	.	DH	DH		AJCC	
3050	Derived SS2000--Flag	RH*	DH	DH	RH	AJCC	
3100	Archive FIN	.	R	.	R	CoC	
3105	NPI--Archive FIN	.	R	.	R	CMS	
3165	ICD Revision Comorbid	.	.	.		CoC	
3170	RX Date Mst Defn Srg	R*	R	R*	R	CoC	
3180	RX Date Surg Disch	.	R	.	R	CoC	
3190	Readm Same Hosp 30 Days	.	R	.	R	CoC	
3220	RX Date Rad Ended	.	R	.	R	CoC	
3230	RX Date Systemic	.	R	RC	R	CoC	
3250	RX Summ--Transplnt/Endocr	R	R	R	R	CoC	
3270	RX Summ--Palliative Proc	.	R	.	R	CoC	
3280	RX Hosp--Palliative Proc	.	R	.	R	CoC	

3300	RuralUrban Continuum 1993	D	.	D		NAACCR	
3310	RuralUrban Continuum 2003	D	.	D		NAACCR	
3312	RuralUrban Continuum 2013	D	.	D		NAACCR	
3400	Derived AJCC-7 T	RH*	DH	DH	RH	AJCC	
3402	Derived AJCC-7 T Descript	RH*	DH	DH	RH	AJCC	
3410	Derived AJCC-7 N	RH*	DH	DH	RH	AJCC	
3412	Derived AJCC-7 N Descript	RH*	DH	DH	RH	AJCC	
3420	Derived AJCC-7 M	RH*	DH	DH	RH	AJCC	
3422	Derived AJCC-7 M Descript	RH*	DH	DH	RH	AJCC	
3430	Derived AJCC-7 Stage Grp	RH*	DH	DH	RH	AJCC	
3605	Derived SEER Path Stg Grp	.	.	DH		SEER	
3610	Derived SEER Clin Stg Grp	.	.	DH		SEER	
3614	Derived SEER Cmb Stg Grp	.	.	DH		SEER	
3616	Derived SEER Combined T	.	.	DH		SEER	
3618	Derived SEER Combined N	.	.	DH		SEER	
3620	Derived SEER Combined M	.	.	DH		SEER	
3622	Derived SEER Cmb T Src	.	.	DH		SEER	
3624	Derived SEER Cmb N Src	.	.	DH		SEER	
3626	Derived SEER Cmb M Src	.	.	DH		SEER	
3700	SEER Site-Specific Fact 1	.	.	R	R	SEER	
3702	SEER Site-Specific Fact 2	.	.	.		SEER	
3704	SEER Site-Specific Fact 3	.	.	.		SEER	
3706	SEER Site-Specific Fact 4	.	.	.		SEER	
3708	SEER Site-Specific Fact 5	.	.	.		SEER	
3710	SEER Site-Specific Fact 6	.	.	.		SEER	
3750	Over-ride CS 1	.	RH	.	RH	AJCC	
3751	Over-ride CS 2	.	RH	.	RH	AJCC	
3752	Over-ride CS 3	.	RH	.	RH	AJCC	
3753	Over-ride CS 4	.	RH	.	RH	AJCC	
3754	Over-ride CS 5	.	RH	.	RH	AJCC	
3755	Over-ride CS 6	.	RH	.	RH	AJCC	
3756	Over-ride CS 7	.	RH	.	RH	AJCC	
3757	Over-ride CS 8	.	RH	.	RH	AJCC	
3758	Over-ride CS 9	.	RH	.	RH	AJCC	
3759	Over-ride CS 10	.	RH	.	RH	AJCC	
3760	Over-ride CS 11	.	RH	.	RH	AJCC	
3761	Over-ride CS 12	.	RH	.	RH	AJCC	
3762	Over-ride CS 13	.	RH	.	RH	AJCC	
3763	Over-ride CS 14	.	RH	.	RH	AJCC	
3764	Over-ride CS 15	.	RH	.	RH	AJCC	
3765	Over-ride CS 16	.	RH	.	RH	AJCC	

3766	Over-ride CS 17	.	RH	.	RH	AJCC	
3767	Over-ride CS 18	.	RH	.	RH	AJCC	
3768	Over-ride CS 19	.	RH	.	RH	AJCC	
3769	Over-ride CS 20	RH	RH	RH	RH	AJCC/NPCR	
3780	Secondary Diagnosis 1	.	R	R*	R	CoC	
3782	Secondary Diagnosis 2	.	R	R*	R	CoC	
3784	Secondary Diagnosis 3	.	R	R*	R	CoC	
3786	Secondary Diagnosis 4	.	R	R*	R	CoC	
3788	Secondary Diagnosis 5	.	R	R*	R	CoC	
3790	Secondary Diagnosis 6	.	R	R*	R	CoC	
3792	Secondary Diagnosis 7	.	R	R*	R	CoC	
3794	Secondary Diagnosis 8	.	R	R*	R	CoC	
3796	Secondary Diagnosis 9	.	R	R*	R	CoC	
3798	Secondary Diagnosis 10	.	R	R*	R	CoC	
3800	Schema ID	D	D	D		NAACCR	
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	.	RS	RS	R	NAACCR	
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	.	RS	RS	R	NAACCR	
3803	Adenoid Cystic Basaloid Pattern	.	RS	RC	R	NAACCR	
3804	Adenopathy	.	RS	RS	R	NAACCR	
3805	AFP Post-Orchiectomy Lab Value	.	RS	RC	R	NAACCR	
3806	AFP Post-Orchiectomy Range	.	RS	RC	R	NAACCR	
3807	AFP Pre-Orchiectomy Lab Value	.	RS	RC	R	NAACCR	
3808	AFP Pre-Orchiectomy Range	.	RS	RC	R	NAACCR	
3809	AFP Pretreatment Interpretation	.	RS	RC	R	NAACCR	
3810	AFP Pretreatment Lab Value	.	RS	RC	R	NAACCR	
3811	Anemia	.	RS	RS	R	NAACCR	
3812	B symptoms	.	RS	RS	R	NAACCR	
3813	Bilirubin Pretreatment Total Lab Value	.	RS	RC	R	NAACCR	
3814	Bilirubin Pretreatment Unit of Measure	.	RS	RC	R	NAACCR	
3815	Bone Invasion	.	RS	RC	R	NAACCR	
3816	Brain Molecular Markers	RS	.	RS	R	NAACCR	
3817	Breslow Tumor Thickness	RS	RS	RS	R	NAACCR	
3818	CA-125 Pretreatment Interpretation	.	RS	RS	R	NAACCR	
3819	CEA Pretreatment Interpretation	.	RS	RS	R	NAACCR	
3820	CEA Pretreatment Lab Value	.	RS	RS	R	NAACCR	
3821	Chromosome 3 Status	.	RS	.	R	NAACCR	
3822	Chromosome 8q Status	.	RS	.	R	NAACCR	
3823	Circumferential Resection Margin (CRM)	.	RS	RS	R	NAACCR	
3824	Creatinine Pretreatment Lab Value	.	RS	RC	R	NAACCR	
3825	Creatinine Pretreatment Unit of Measure	.	RS	RC	R	NAACCR	
3826	Estrogen Receptor Percent Positive or Range	.	RS	RC	R	NAACCR	

3827	Estrogen Receptor Summary	RS	RS	RS	R	NAACCR	
3828	Estrogen Receptor Total Allred Score	.	RS	RH	RH	NAACCR	
3829	Esophagus and EGJ Tumor Epicenter	RS	RS	RS	R	NAACCR	
3830	Extranodal Extension Clin (non-Head and Neck)	.	RS	RC	R	NAACCR	
3831	Extranodal Extension Head and Neck Clinical	.	RS	RC	R	NAACCR	
3832	Extranodal Extension Head and Neck Pathological	.	RS	RC	R	NAACCR	
3833	Extranodal Extension Path (non-Head and Neck)	.	RS	RC	R	NAACCR	
3834	Extravascular Matrix Patterns	.	RS	.	R	NAACCR	
3835	Fibrosis Score	RS	RS	.	R	NAACCR	
3836	FIGO Stage	.	RS	RC	R	NAACCR	
3837	Gestational Trophoblastic Prognostic Scoring Index	.	RS	RS	R	NAACCR	
3838	Gleason Patterns Clinical	RS	RS	RS	R	NAACCR	
3839	Gleason Patterns Pathological	RS	RS	RS	R	NAACCR	
3840	Gleason Score Clinical	RS	RS	RS	R	NAACCR	
3841	Gleason Score Pathological	RS	RS	RS	R	NAACCR	
3842	Gleason Tertiary Pattern	RS*	RS	RC	R	NAACCR	
3843	Grade Clinical	R	R	R	R	NAACCR	
3844	Grade Pathological	R	R	R	R	NAACCR	
3845	Grade Post Therapy Path (yp)	R*	R	RS	R	NAACCR	
3846	hCG Post-Orchiectomy Lab Value	.	RS	RC	R	NAACCR	
3847	hCG Post-Orchiectomy Range	.	RS	RC	R	NAACCR	
3848	hCG Pre-Orchiectomy Lab Value	.	RS	RC	R	NAACCR	
3849	hCG Pre-Orchiectomy Range	.	RS	RC	R	NAACCR	
3850	HER2 IHC Summary	.	.	.		NAACCR	
3851	HER2 ISH Dual Probe Copy Number	.	.	.		NAACCR	
3852	HER2 ISH Dual Probe Ratio	.	.	.		NAACCR	
3853	HER2 ISH Single Probe Copy Number	.	.	.		NAACCR	
3854	HER2 ISH Summary	.	.	.		NAACCR	
3855	HER2 Overall Summary	RS	RS	RS	R	NAACCR	
3856	Heritable Trait	.	RS	RS	R	NAACCR	
3857	High Risk Cytogenetics	.	RS	RS	R	NAACCR	
3858	High Risk Histologic Features	.	RS	RC	R	NAACCR	
3859	HIV Status	.	.	.		NAACCR	
3860	International Normalized Ratio Prothrombin Time	.	RS	RC	R	NAACCR	
3861	Ipsilateral Adrenal Gland Involvement	.	RS	RC	R	NAACCR	
3862	JAK2	.	RS	RS	R	NAACCR	
3863	Ki-67	.	RS	RS	R	NAACCR	
3864	Invasion Beyond Capsule	.	RS	RC	R	NAACCR	
3865	KIT Gene Immunohistochemistry	.	RS	RC	R	NAACCR	
3866	KRAS	.	RS	RS	R	NAACCR	
3867	LDH Post-Orchiectomy Range	.	RS	RC	R	NAACCR	

3868	LDH Pre-Orchiectomy Range	.	RS	RC	R	NAACCR	
3869	LDH Level	.	RS	RS	R	NAACCR	
3870	LDH Upper Limits of Normal	.	RS	RC	R	NAACCR	
3871	LN Assessment Method Femoral-Inguinal	.	RS	RC	R	NAACCR	
3872	LN Assessment Method Para-Aortic	.	RS	RC	R	NAACCR	
3873	LN Assessment Method Pelvic	.	RS	RC	R	NAACCR	
3874	LN Distant Assessment Method	.	RS	RC	R	NAACCR	
3875	LN Distant: Mediastinal, Scalene	.	RS	RC	R	NAACCR	
3876	LN Head and Neck Levels I-III	.	RS	RC	R	NAACCR	
3877	LN Head and Neck Levels IV-V	.	RS	RC	R	NAACCR	
3878	LN Head and Neck Levels VI-VII	.	RS	RC	R	NAACCR	
3879	LN Head and Neck Other	.	RS	RC	R	NAACCR	
3880	LN Isolated Tumor Cells (ITC)	.	RS	RC	R	NAACCR	
3881	LN Laterality	.	RS	.	R	NAACCR	
3882	LN Positive Axillary Level I-II	.	RS	RS	R	NAACCR	
3883	LN Size	.	RS	RC	R	NAACCR	
3885	Lymphocytosis	.	RS	RS	R	NAACCR	
3886	Major Vein Involvement	.	RS	RC	R	NAACCR	
3887	Measured Basal Diameter	.	RS	RS	R	NAACCR	
3888	Measured Thickness	.	RS	RS	R	NAACCR	
3889	Methylation of O6-Methylguanine-Methyltransferase	.	RS	RS	R	NAACCR	
3890	Microsatellite Instability (MSI)	RS*	RS	RS	R	NAACCR	
3891	Microvascular Density	.	RS	.	R	NAACCR	
3892	Mitotic Count Uveal Melanoma	.	RS	RC	R	NAACCR	
3893	Mitotic Rate Melanoma	.	RS	RS	R	NAACCR	
3894	Multigene Signature Method	.	RS	.	R	NAACCR	
3895	Multigene Signature Results	.	RS	.	R	NAACCR	
3896	NCCN International Prognostic Index (IPI)	.	RS	RC	R	NAACCR	
3897	Number of Cores Examined	.	RS	RS	R	NAACCR	
3898	Number of Cores Positive	.	RS	RS	R	NAACCR	
3899	Number of Examined Para-Aortic Nodes	.	RS	RC	R	NAACCR	
3900	Number of Examined Pelvic Nodes	.	RS	RC	R	NAACCR	
3901	Number of Positive Para-Aortic Nodes	.	RS	RC	R	NAACCR	
3902	Number of Positive Pelvic Nodes	.	RS	RC	R	NAACCR	
3903	Oncotype Dx Recurrence Score-DCIS	.	RS	.	R	NAACCR	
3904	Oncotype Dx Recurrence Score-Invasive	.	RS	RS	R	NAACCR	
3905	Oncotype Dx Risk Level-DCIS	.	.	.		NAACCR	
3906	Oncotype Dx Risk Level-Invasive	.	.	.		NAACCR	
3907	Organomegaly	.	RS	RS	R	NAACCR	
3908	Percent Necrosis Post Neoadjuvant	.	.	.		NAACCR	
3909	Perineural Invasion	.	RS	RS	R	NAACCR	

3910	Peripheral Blood Involvement	.	RS	RS	R	NAACCR	
3911	Peritoneal Cytology	.	RS	RS	R	NAACCR	
3913	Pleural Effusion	.	RS	RS	R	NAACCR	
3914	Progesterone Receptor Percent Positive or Range	.	RS	RC	R	NAACCR	
3915	Progesterone Receptor Summary	RS	RS	RS	R	NAACCR	
3916	Progesterone Receptor Total Allred Score	.	RS	RH	RH	NAACCR	
3917	Primary Sclerosing Cholangitis	.	RS	.	R	NAACCR	
3918	Profound Immune Suppression	.	RS	RC	R	NAACCR	
3919	EOD Prostate Pathologic Extension	.	.	RS	R	SEER	
3920	PSA (Prostatic Specific Antigen) Lab Value	RS	RS	RS	R	NAACCR	
3921	Residual Tumor Volume Post Cyto reduction	.	RS	RC	R	NAACCR	
3922	Response to Neoadjuvant Therapy	.	RS	RC	R	NAACCR	
3923	S Category Clinical	.	RS	RS	R	NAACCR	
3924	S Category Pathological	.	RS	RS	R	NAACCR	
3925	Sarcomatoid Features	.	RS	RS	R	NAACCR	
3926	Schema Discriminator 1	RS	RS	RS	R	NAACCR	
3927	Schema Discriminator 2	RS	RS	RS	R	NAACCR	
3928	Schema Discriminator 3	.	RS	RS	R	NAACCR	
3929	Separate Tumor Nodules	.	RS	RC	R	NAACCR	
3930	Serum Albumin Pretreatment Level	.	RS	RS	R	NAACCR	
3931	Serum Beta-2 Microglobulin Pretreatment Level	.	RS	RS	R	NAACCR	
3932	LDH Lab Value	RS	RS	RC	R	NAACCR	
3933	Thrombocytopenia	.	RS	RS	R	NAACCR	
3934	Tumor Deposits	.	RS	RC	R	NAACCR	
3935	Tumor Growth Pattern	.	RS	.	R	NAACCR	
3936	Ulceration	.	RS	RS	R	NAACCR	
3937	Visceral and Parietal Pleural Invasion	.	RS	RC	R	NAACCR	
3938	ALK Rearrangement	.	RS	R	R	NAACCR	
3939	EGFR Mutational Analysis	.	RS	R	R	NAACCR	
3940	BRAF Mutational Analysis	.	RS	R	R	NAACCR	
3941	NRAS Mutational Analysis	.	RS	R	R	NAACCR	
3942	CA 19-9 PreTX Lab Value	.	RS	R	R	NAACCR	
3943	NCDB--SARSCoV2--Test	.	RH	RH*	RH	CoC	
3944	NCDB--SARSCoV2--Pos	.	RH	RH*	RH	CoC	
3945	NCDB--SARSCoV2--Pos Date	.	RH	RH*	RH	CoC	
3946	NCDB--COVID19--Tx Impact	.	RH	RH*	RH	CoC	
3950	Macroscopic Evaluation of Mesorectum	.	R	RC	R	CoC	
3955	Derived Rai Stage	.	.	D		NAACCR	
3956	p16	RS	RS	RS	R	SEER	
3957	LN Status Pelvic	.	RS	RC	R	SEER	
3958	LN Status Para-Aortic	.	RS	RC	R	SEER	

3959	LN Status Femoral-Inguinal	.	RS	RC	R	SEER	
3960	Histologic Subtype	RS*	RS	RS	R	SEER	
3961	Clinical Margin Width	.	RS	RC	R	CoC	
3964	Brain Primary Tumor Location	RS	R	RS	R	SEER	
7010	Path Reporting Fac ID 1	.	.	.		HL7	
7011	Path Reporting Fac ID 2	.	.	.		HL7	
7012	Path Reporting Fac ID 3	.	.	.		HL7	
7013	Path Reporting Fac ID 4	.	.	.		HL7	
7014	Path Reporting Fac ID 5	.	.	.		HL7	
7090	Path Report Number 1	.	.	.		HL7	
7091	Path Report Number 2	.	.	.		HL7	
7092	Path Report Number 3	.	.	.		HL7	
7093	Path Report Number 4	.	.	.		HL7	
7094	Path Report Number 5	.	.	.		HL7	
7100	Path Order Phys Lic No 1	.	.	.		HL7	
7101	Path Order Phys Lic No 2	.	.	.		HL7	
7102	Path Order Phys Lic No 3	.	.	.		HL7	
7103	Path Order Phys Lic No 4	.	.	.		HL7	
7104	Path Order Phys Lic No 5	.	.	.		HL7	
7190	Path Ordering Fac No 1	.	.	.		HL7	
7191	Path Ordering Fac No 2	.	.	.		HL7	
7192	Path Ordering Fac No 3	.	.	.		HL7	
7193	Path Ordering Fac No 4	.	.	.		HL7	
7194	Path Ordering Fac No 5	.	.	.		HL7	
7320	Path Date Spec Collect 1	.	.	.		HL7	
7321	Path Date Spec Collect 2	.	.	.		HL7	
7322	Path Date Spec Collect 3	.	.	.		HL7	
7323	Path Date Spec Collect 4	.	.	.		HL7	
7324	Path Date Spec Collect 5	.	.	.		HL7	
7480	Path Report Type 1	.	.	.		HL7	
7481	Path Report Type 2	.	.	.		HL7	
7482	Path Report Type 3	.	.	.		HL7	
7483	Path Report Type 4	.	.	.		HL7	
7484	Path Report Type 5	.	.	.		HL7	
9960	Height	.	.	.	R	NPCR	
9961	Weight	.	.	.	R	NPCR	

.	No recommendation
D	Derived
D*	Derived, when available
R	Required
R#	Required; central registries may code available data using either SEER or CoC data items and associated rules
R*	Required, when available
R^	Required, these text requirements may be met with one or several text block fields
RC	Collected by SEER from CoC-accredited hospitals
RH	Historically collected and currently transmitted
RH*	Historically collected and currently transmitted when available
RS	Required, site specific
RS*	Required, site specific; when available
S	Supplementary/recommended